On February 11, 2026, the Seventh Circuit Court of Appeals scrutinized the duration of a settlement agreement between Teva Pharmaceuticals USA Inc. and Eli Lilly & Co. concerning the osteoporosis medication Forteo. The panel questioned Teva’s counsel on the reasonableness of the agreement’s longevity, especially since Teva’s generic version was not market-ready until several years after the original patent dispute had been resolved.
This appellate review follows a July 2025 decision by an Indiana federal judge, who dismissed Teva’s lawsuit alleging that Eli Lilly breached the settlement agreement. The court determined that Eli Lilly’s commitment to waive exclusivity for Teva concluded with the expiration of the relevant patents. The judge stated that, absent the 2019 patent expiration date, the settlement lacked a defined end point, and the “only plausible reading” was that the agreement terminated alongside the patents.
The case, titled Teva Pharmaceuticals USA Inc. v. Eli Lilly and Co., is being heard under case number 25-2125 in the U.S. Court of Appeals for the Seventh Circuit. The outcome of this appeal could have significant implications for the pharmaceutical industry, particularly regarding the structuring and duration of settlement agreements between brand-name and generic drug manufacturers.
Historically, the pharmaceutical sector has seen numerous legal battles over patent settlements. For instance, in 2017, Eli Lilly reached a settlement in a Virginia federal court concerning its erectile dysfunction drug, Cialis. The agreement maintained market exclusivity until at least September 2018, adjusting the original patent expiration date of April 2020. Such settlements often aim to balance the interests of patent holders and generic manufacturers, but they can also lead to complex legal disputes over their terms and durations.
As the Seventh Circuit deliberates on the Teva-Eli Lilly case, the industry awaits guidance on how courts may interpret the temporal scope of patent settlement agreements, especially when generic products enter the market years after the original disputes are settled.